Cross-Talk between LOX-1 and PCSK9 in vascular tissues

Cardiovascular Research

Volumn 107, Issue 4, 2015, Pages 556-567

  Ding, Zufeng ^a,b   Liu, Shijie ^a,b   Wang, Xianwei ^a   Deng, Xiaoyan ^b   Fan, Yubo ^b   Shahanawaz, Jiwani ^a   Reis, Robert J Shmookler ^a   Varughese, Kattayi I ^a   Sawamura, Tatsuya ^c   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b BEIHANG UNIVERSITY   (China)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

LOX 1; Mitochondrial ROS; PCSK9; VCAM 1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PEPTIDES AND PROTEINS; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; OLR1 PROTEIN, MOUSE; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR TISSUE; ANIMAL; CELL CULTURE; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; SMOOTH MUSCLE CELL;

ANIMALS; CELLS, CULTURED; ENDOTHELIAL CELLS; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MICE; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS E; SERINE ENDOPEPTIDASES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84948128946     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv178     Document Type: Article

References (28)

1. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997;386:73-77.
2. Ding Z, Liu S, Wang X, Khaidakov M, Dai Y, Mehta JL. Role of oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. Sci Rep 2013;3: 1077.
3. Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, Satoh H, Inoue K, Kawase Y, Jishage K, Suzuki H, Takeya M, Schnackenberg L, Beger R, Hermonat PL, Thomas M, Sawamura T. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007;100:1634-1642.
4. Akhmedov A, Rozenberg I, Paneni F, Camici GG, Shi Y, Doerries C, Sledzinska A, Mocharla P, Breitenstein A, Lohmann C, Stein S, von Lukowicz T, Kurrer MO, Boren J, Becher B, Tanner FC, Landmesser U, Matter CM, Luscher TF. Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. Eur Heart J 2014;35:2839-2848.
5. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116: 2995-3005.
6. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354: 1264-1272.
7. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-18612.
8. Kosenko T, Golder M, Leblond G, WengW, Lagace TA. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem 2013;288: 8279-8288.
9. Stein EA, Raal FJ. Insights into PCSK9, low-density lipoprotein receptor, and lowdensity lipoprotein cholesterol metabolism: of mice and man. Circulation 2013;127: 2372-2374.
10. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013;127:2403-2413.
11. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C. Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008;374:341-344.
12. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83: 456S-460S.
13. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001;107:1209-1210.
14. Rosanna DP, Salvatore C. Reactive oxygen species, inflammation, and lung diseases. Curr Pharm Des 2012;18:3889-3900.
15. Ding Z, Wang X, Schnackenberg L, Khaidakov M, Liu S, Singla S, Dai Y, Mehta JL. Regulation of autophagy and apoptosis in response to ox-LDL in vascular smooth muscle cells, and the modulatory effects of the microRNA hsa-let-7g. Int J Cardiol 2013;168: 1378-1385.
16. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221-225.
17. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, Kita T. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res 1998;83:322-327.
18. Ding Z, Liu S, Wang X, Dai Y, Deng X, Fan Y, Sun C, Wang Y, Mehta JL. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal 2015;22: 760-771.
19. Ding Z, Liu S, Wang X, Dai Y, Khaidakov M, Deng X, Fan Y, Xiang D, Mehta JL. LOX-1, mtDNA damage and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc Res 2014;103:619-628.
20. Pirillo A, Uboldi P, Ferri N, Corsini A, Kuhn H, Catapano AL. Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Biochem Biophys Res Commun 2012;428: 230-233.
21. Li DY, Chen HJ, Mehta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001; 52:130-135.
22. Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis 2012;220:381-386.
23. Hu C, Dandapat A, Sun L, Chen J, Marwali MR, Romeo F, Sawamura T, Mehta JL. LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in lowdensity lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc Res 2008;79:287-293.
24. Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem 2012;359:347-358.
25. Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, Borghi P, Ramoni C, Filesi I, Biocca S, Gabriele L, Belardelli F. LOX-1 as a natural IFN-Alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 2010;115: 1554-1563.
26. Hong D, Bai YP, Gao HC, Wang X, Li LF, Zhang GG, Hu CP. Ox-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. Atherosclerosis 2014;235:310-317.
27. Ding Z, Liu S, Sun C, Chen Z, Fan Y, Deng X, Wang X, Mehta JL. Concentration polarization of ox-LDL activates autophagy and apoptosis via regulating LOX-1 expression. Sci Rep 2013;3:2091.
28. Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, Honda Y, Butcher EC, Masaki T, Sawamura T. Lectin-like oxidized LDL receptor-1 is a cell-Adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA 2003;100:1274-1279.